Leading Academic Clinical Training Hospital, Universitair Ziekenhuis Brussels, Purchases ViewRay’s MRIdian Linac

Ziekenhuis Brussels has purchased a
MRIdian® Linac MRI-Guided Therapy System, a cutting-edge radiation therapy device that combines the latest innovations in precision radiation
delivery and ground-breaking MR-guidance.

November 10, 2020
Universitair Ziekenhuis Brussels in Belgium Aims to Begin MRIdian Patient Treatments in 2021
CLEVELAND, Nov. 10, 2020 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) announced today that Universitair
Universitair Ziekenhuis Brussels (UZB) Hospital has a long history of leading the introduction of new and groundbreaking technologies to the Belgian
radiation therapy market.
“Even in these difficult times we stand strong to our mission to offer the best technologies to our cancer patients,” said Prof. Marc Noppen, M.D.,
Ph.D., Chief Executive Officer of UZB.
“We believe adding MRIdian to our portfolio of cancer treatments will expand the population of patients we can treat. Through the use of MRI-guidance
and on-table adaptive capabilities, we can improve the accuracy with which we deliver radiation, deliver higher-doses than previously feasible, and
reach tumors that were otherwise unreachable,” said Prof. Dr. M. De Ridder, head of radiation oncology at UZB. “We look forward to collaborating with
ViewRay to support future technology development and advance the practice of MRI-guided radiation therapy.”
Unlike conventional radiation therapy systems, MRIdian combines an MRI system with a radiation therapy system. Together with other technical
innovations, this offers advantages for the delivery of safe and effective radiotherapy, including the ability to see the tumor and surrounding tissue
during treatment, adaptation of the therapy in response to changes in patient anatomy and tumor size between treatments, continuous tracking of the
tumor during treatment, and automatic pausing of the radiation if the tumor moves outside of the boundary. As a result, the system delivers ablative,
high-dose radiation to the tumor while protecting the surrounding healthy tissue from damage.
“We’re pleased to welcome UZB to our community of centers integrating MRIdian into their radiation oncology program,” said Paul Ziegler, Senior Vice
President of Sales and Marketing at ViewRay. “They have a proven clinical pedigree in effectively treating historically difficult to treat tumors and we
believe MRIdian will be the perfect complement to that expertise.”
Currently 40 MRIdian systems are installed at hospitals around the world, where they are used to treat a wide variety of solid tumors and are the focus
of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts and
presentations. More than 11,000 patients have been treated with MRIdian. For a list of treatment centers, please visit:
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary
high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation
oncology. Unlike MR systems used in diagnostic radiology, MRIdian’s high-definition MR was purpose built to address specific challenges, including
beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and
MRIdian are registered trademarks of ViewRay, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements
in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the
rate of new orders, upgrades, and installations, ViewRay’s anticipated future operating and financial performance, and ViewRay’s conference calls to
discuss its quarterly results. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors
include, among others, the ability to commercialize MRIdian Linac System, demand for ViewRay’s products, the ability to convert backlog into revenue,
the timing of delivery of ViewRay’s products, the timing, length, and severity of the recent COVID-19 (coronavirus) pandemic, including its impacts
across our businesses on demand, operations and our global supply chains, the results and other uncertainties associated with clinical trials, the
ability to raise the additional funding needed to continue to pursue ViewRay’s business and product development plans, the inherent uncertainties
associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a
further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as
well as risks relating to ViewRay’s business in general, see ViewRay’s current and future reports filed with the Securities and Exchange Commission,
including its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and its Quarterly Reports on Form 10-Q, as updated
periodically with the company’s other filings with the SEC. These forward-looking statements are made as of the date of this press release, and
ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those
projected in the forward-looking statements, except as required by law.
View original content to download multimedia:
SOURCE ViewRay, Inc.
Media Enquiries: Karen Hackstaff, Vice President, Strategy and Brand, ViewRay, Inc., 1-844-MRIdian (674-3426), Investor
Relations: Michaella Gallina, Vice President, Chief of Staff, Head of Investor Relations and Communications, ViewRay, Inc., 1-844-MRIdian